CAMP Projects

Projects within CAMP are operated within three work packages (WP1-3) covering scientific and technological challenges and infrastructure around process development and production of ATMP.

Sixteen collaboration projects engaging partners from healthcare, industry and academy have been, or are currently running within WP1-3. The project portfolio will be further developed in 2021.

The current project portfolio consists of the following:

WP1 – Process development


Work package leader – Stefan Scheding

  1. Label-free sorting of stromal cell preparations for clinical use
  2. ATMP for urethra reconstruction with de- and recellularization technique
  3. Development of Multilayered Tissue-Engineered Skin Construct
  4. GMP production of pluripotent stem cells and its derivatives.
  5. Development of producer lines for delivering therapeutic mRNAs through Extracellular Vesicles.
  6. CAR-T cell therapy for malignant melanoma of the skin and the eye.
  7. Value survey – How do donors, patients, the general public and policy makers want to balance different interests?
  8. Extracellular vesicles (CARMEV) for prevention of heart failure.
  9. Scaleable magnetic isolation of differentiated stem cells.

WP2 – Infrastructure for GMP manufacturing


Work package leader – Pontus Blomberg

  1. Developing a Pre-GMP facility for vectors and genetically modified cells
  2. Vecura – An Infrastructure for Development and Manufacturing of ATMPs
  3. Expansion of GMP Compliant – Tumor Infiltrating Lymphocytes (TILs) in Xuri bioreactor
  4. Harmonizing HQ plasmid production between pre-GMP and GMP sites
  5. GMP-compliant infrastructure and production in a hospital-setting of mesenchymal stromal cells from lipoaspirate for use in clinical trials

WP3 – Quality control, shelf-life and logistics

Work package leader – Jim Lund

  1. Establishing a QC and logistics strategy of cell-based products for secure patient treatment
  2. Single cell qPCR characterization of ATMP
  3. Establishing a non-dry ice dependent logistics strategy for cell therapies.

< br />

For more information, with new ideas or to get involved please contact: